Participants 47 159 6
patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus
Participants 175 204 7
36 patients treated in France
Participants 286 338 5
patients with metastatic renal cell carcinoma (mRCC)
Participants 561 626 5
patients with disease progression after a TKI-everolimus sequence
Participants 672 777 4
patients enrolled in RECORD-1 (Renal Cell Cancer Treatment With Oral RAD001 Given Daily) at French sites.
Participants 921 972 4
Thirty-six patients received a TKI after everolimus
